mardi 28 août 2018

Onco Actu du 28 août 2018

1. Biologie

Breast cancer breakthrough: some tumours can stop their own spread [Garvan Institute]

3.1.1 Prévention - Tabac - e-cigs

Almost one in 20 U.S. adults now use e-cigarettes [Reuters]

4.2 Dép., diag. & prono. - Génome

With Rehm as Chief Genomics Officer, MGH Starts Studying Utility of WGS, Plans Genomic Risk Clinic [Genome Web]

5. Traitements

Institute for Clinical and Economic Review Report Finds Evidence Inadequate to Distinguish the Clinical Benefits of Different Antiandrogen Therapies for Men with Nonmetastatic Castration-Resistant Prostate Cancer [ICER]

5.1 Traitements - Pré-clinique

Mass. General study defines mechanisms behind focused-ultrasound-assisted treatment of brain tumors [Mass. General Hospital]

Exploring cancer metabolism [MIT News]

Additional Inhibitor Can Help Anti-VEGF Therapy Overcome Resistance in Deadly Brain Cancer [Penn Medicine]

5.12.1 Immunothérapies - partenariats

Cancer powerhouse Genentech lines up an NK and T cell alliance with Affimed that’s loaded with billions in biobucks [EndPoints]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe [EndPoints]

5.12.5 Immunothérapies - Pharma

Withdrawal of Application for a Change to the EU Marketing Authorisation for Nivolumab [ESMO]

5.12.6 Immunothérapies - AMM

Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy [Gilead]

5.12.8 Immunothérapies - Economie

Harbour BioMed follows cancer drug deals with a hefty $85M Series B backed by Singapore’s GIC [EndPoints]

5.2 Pharma

The Future of Medicine May Land Within Five to 10 Years, Crispr Inventor Says [Bloomberg]

CRISPR biotech Editas to lose CMO as it continues push for clinical trials [FierceBiotech]

Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer [Bayer]

5.2.3 Pharma - économie

Y-mAbs Plans IPO to Advance Two Pediatric Cancer Drugs to the FDA [Xconomy]

Y-mAbs preps $92M IPO to push lead assets through regulatory filing [FierceBiotech]

5.3.4 Traitements - AMM (FDA, EMA,...)

AbbVie, Johnson & Johnson grab another Imbruvica nod with early OK in rare blood cancer [FiercePharma]

U.S. FDA Approves IMBRUVICA (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström's Macroglobulinemia, a Rare Blood Cancer [Janssen]

6. Lutte contre les cancers

Returning Individual Research Results to Participants Guidance for a New Research Paradigm (2018) [National Academies Press]

6.5 Médecines alternatives

Confronting homeopathy, naturopathy, homeopathy, and other quackademic medicine at my alma mater [Science-Based Medicine]

6.6 Publications

The Science Behind Social Science Gets Shaken Up—Again [Wired]

In Psychology And Other Social Sciences, Many Studies Fail The Reproducibility Test [NPR]

‘Generous’ approach to replication confirms many high-profile social science findings [Science]

Attempt to replicate major social scientific findings of past decade fails [The Guardian]

Online Bettors Can Sniff Out Weak Psychology Studies [The Atlantic]

Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015 [Nature Human Behaviour]

6.9 Controverses

NIH investigating whether U.S. scientists are sharing ideas with foreign governments [Science]